Xlumena said it closed a $25 million Series C round it plans to use to expand its commercial footprint and win FDA clearance for its Axios stent and delivery system.
Charter Life Sciences
Mirabilis Medica said it raised up to $13 million in a Series A1 round and tapped a new CEO to lead the development of its ultrasound treatment for uterine fibroids.
The Bothell, Wash.-based medical device company said it closed on an initial $7 million round led by GSR Ventures, including $4 million in cash and a $3 million conversion of debt to equity. Charter Life Sciences also participated in the round.